Loading...
Sedating antidepressants tend to cause psychomotor impairment, including in drivers. In an industry-funded study, researchers examined psychomotor function while driving in 24 healthy volunteers who received 2 weeks' treatment at bedtime with 10 mg of the new antidepressant vortioxetine, 30 mg of mirtazapine, or placebo. Not yet FDA-approved, vortioxetine is a bis-aryl-sulfanyl amine that acts as a serotonin (5-HT) transporter inhibitor, a 5-HT1A receptor agonist, a 5-HT1B receptor partial agonist, and an antagonist of 5-HT3, 5-HT7, and 5-HT1D receptors.
Mirtazapine was associated with greater road tracking errors than placebo on treatment day 2 but not after day 15, with worse performance than placebo on critical tracking and reaction time …